RGT
Click for more information
17.7% 30.0¢ argent biopharma limited

Ann: Investor Presentation - March 2017, page-2

  1. mutek
    65 Posts.
    clock Created with Sketch.
    27/03/17
    10:46
    Post #: 23643159
    Near-term growth catalysts:

    • Major announcements and strategic partnerships to be completed for MXC’s Australian medical cannabis genetics and breeding research, clinical trials, and production strategy

    • Plans to commence first Australian MC clinical trials in 2017 – with leading medical institutions

    Sentiment - accumulate
    MXC Price at posting: 7.4¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

SFX Sheffield Resources achieves milestone production, shipments at Thunderbird, WA
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
HMD HeraMED delivers digital maternity care to select clinics with Telstra
right-arrow Created with Sketch.
NIM Nimy extends sulphide targets at Mons with new anomalies identified
right-arrow Created with Sketch.
MYR Myer lobs proposed merger at major shareholder Premier Investments
right-arrow Created with Sketch.
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
(20min delay)
Last
30.0¢ 		Change
0.045(17.7%) 		Mkt cap ! $13.58M
Open High Low Value Volume
25.5¢ 30.0¢ 25.5¢ $1.492K 5.713K

Buyers (Bids)

No. Vol. Price($)
1 1292 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 5 1
View Market Depth
Last trade - 15.36pm 27/06/2024 (20 minute delay) ?
RGT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.